Skip to content
Peptigraph home

Retatrutide 5 mg Vial: Reconstitution and Dosing Chart

How much bacteriostatic water to add to a 5 mg vial of Retatrutide, the concentration you get, and a full dose-to-units chart.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP / glucagon triple agonistUpdated
Vial size
5 mg
With 2 mL water
2.5 mg/mL
common choice
10 units contain
0.25 mg
at 2 mL, U-100
Whole vial
200 units
2 mL on a U-100 scale

How much water to add

Bacteriostatic water only changes the concentration, not the amount of Retatrutide in the vial. More water means more units per dose (easier to read), less water means fewer.

Retatrutide 5 mg vial: concentration by water added
Water addedConcentration10 units contain1 mg isWhole vial
1 mL5 mg/mL0.5 mg20 u100 u
2 mL2.5 mg/mL0.25 mg40 u200 u
2.5 mL2 mg/mL0.2 mg50 u250 u
3 mL1.667 mg/mL0.167 mg60 u300 u

Calculator and full dosing table

Preset to the 5 mg vial. Change any value; the table below the result updates with it.

1Vial size
2Bacteriostatic water added
3Dose per injection
4Syringe (U-100)
Draw to
80units
= 0.8 mL on a 1 mL U-100 insulin syringe
5 mg vial2 mL water2 mg dose
Concentration
2.5 mg/mL
Doses per vial
2
Weeks (1 dose/wk)
2
Math only. It does not recommend a dose.

80 units (0.8 mL) on a 1 mL U-100 syringe: 2 mg from a 5 mg vial + 2 mL water (Retatrutide).

Dosing table for a 5 mg vial

Syringe units (U-100) for each dose, by how much bacteriostatic water you add.

Retatrutide: U-100 syringe units per dose for a 5 mg vial
Dose1 mL water2 mL water2.5 mL water3 mL water
0.5 mg10202530
1 mg20405060
2 mg4080100120
4 mg80160200240

How the math works

Concentration is the vial's milligrams divided by the water you add. Volume to draw is your dose divided by that concentration. On a U-100 syringe, 1 mL is 100 units, so units = mL × 100.

5 mg ÷ 2 mL = 2.5 mg/mL
2 mg ÷ 2.5 mg/mL = 0.8 mL
0.8 mL × 100 = 80 units
80 units · 0.8 mL · 2 mg from 5 mg + 2 mL
Math only. The amounts in these tables are reference values for the arithmetic, not dose recommendations.

Where the doses for a 5 mg retatrutide vial come from

In the 48-week phase 2 trial, retatrutide arms from 1 mg to 12 mg were given by subcutaneous injection once weekly.[1]

Retatrutide trial doses converted to syringe units (5 mg vial)

A 2 mg starting dose, then 4 mg, 8 mg and 12 mg, is how one phase 2 obesity arm is described in its registry record; the chart therefore lists 2 mg too.[3]

1 mg from a 5 mg vial: 5 doses; 20 / 40 / 60 units at 1 / 2 / 3 mL of water.

Calculated from vial mg 5; dose mg 1; water mL 1, 2, 3; u100 units per mL 100; dose source trial doses quoted on this page (1 mg, 2 mg step-up start, 4, 8, 9, 12 mg). Formula: full doses = floor(vialMg / doseMg); leftover = vialMg - doses x doseMg; units = doseMg / (vialMg / waterMl) x 100; flag units < 5 or > 100

2 mg from a 5 mg vial: 2 doses, 1 mg left over; 40 / 80 / 120 (>100, over one 1 mL syringe) units at 1 / 2 / 3 mL of water.

Calculated from vial mg 5; dose mg 2; water mL 1, 2, 3; u100 units per mL 100; dose source trial doses quoted on this page (1 mg, 2 mg step-up start, 4, 8, 9, 12 mg). Formula: full doses = floor(vialMg / doseMg); leftover = vialMg - doses x doseMg; units = doseMg / (vialMg / waterMl) x 100; flag units < 5 or > 100

4 mg from a 5 mg vial: 1 dose, 1 mg left over; 80 / 160 (>100, over one 1 mL syringe) / 240 (>100, over one 1 mL syringe) units at 1 / 2 / 3 mL of water.

Calculated from vial mg 5; dose mg 4; water mL 1, 2, 3; u100 units per mL 100; dose source trial doses quoted on this page (1 mg, 2 mg step-up start, 4, 8, 9, 12 mg). Formula: full doses = floor(vialMg / doseMg); leftover = vialMg - doses x doseMg; units = doseMg / (vialMg / waterMl) x 100; flag units < 5 or > 100

Every row for the 5 mg vial is a trial dose converted to syringe units, not a schedule to follow.

Calculated from vial mg 5. Formula: presentation note; see rows above

For retatrutide, 8 mg, 9 mg and 12 mg are larger than the whole 5 mg vial.

Calculated from vial mg 5; doses mg 8, 9, 12. Formula: doseMg > vialMg

Is 5 mg a labelled retatrutide strength?

With 0 matching applications in Drugs@FDA there is no labelled strength to compare a 5 mg retatrutide vial with.

Calculated from vial mg 5; drugs fda matches 0; source s2-legal/api.fda.gov/drugsfda-retatrutide.txt. Formula: labelled strengths available = 0

Market price of 5 mg vials

Single-vial listings at 5 mg had a median of $91.00 across 15 listings (range $34.00 to $139.99), or $18.20 per mg, in the price dataset checked 2026-10-02.

Calculated from source our price listings dataset; peptide retatrutide; vial mg 5; median 91; listings 15; min 34; max 139.99; median per mg 18.2. Formula: median / vialMg = medianPerMg

Common questions

How much water goes in a 5 mg vial of Retatrutide?

That choice only changes the concentration. With 2 mL, a 5 mg vial is 2.5 mg/mL; with 1 mL it is 5 mg/mL. Less water means fewer units per dose and harder-to-read marks for small doses.

How many units is 1 mg from a 5 mg vial?

With 2 mL of water, 1 mg is 40 units on a U-100 syringe. With other water amounts, see the table.

How many doses are in a 5 mg vial?

Divide the vial size by the dose (in the same unit). The calculator on this page shows the number of whole doses for any dose you pick.

How do you reconstitute reta 5mg?

With 2 mL of water the 5 mg retatrutide vial is 2.5 mg/mL, so each 0.01 mL unit holds 25 mcg.

Calculated from vial mg 5; water mL 2. Formula: mcg per unit = vialMg / waterMl x 10

What is the dosage for reta 5mg?

The doses used here (1, 4, 8, 9 and 12 mg) are trial arms, not recommendations; the 5 mg vial table shows how each divides.

Calculated from vial mg 5; doses mg 1, 4, 8, 9, 12. Formula: see vial table

More on Retatrutide

Sources

  1. 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
  3. 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (NCT04881760; arms and posted results)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  4. 4Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  5. 5BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.